Uncategorized

Nuvectis, Haisco ink up to $1.4B deal for two late-stage programs

Published

2 days ago

on

June 22, 2026

By

Temp User

China’s Haisco Pharmaceutical continues to wield deals, this time out-licensing rights to two late-stage programs to New Jersey biotech Nuvectis.

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Endpoints News3 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized3 months ago

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State

Exit mobile version